Drugs / FB1001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06506305 | Aug 2024 → Jun 2026 overdue | non-arteritic anterior ischemic optic neuropathy, primary angle-closure glaucoma | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FB1001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06506305 ↗ |
| Modality | Monoclonal antibody | “FB1001 is a recombinant humanized monoclonal antibody” NCT06506305 ↗ |
| Route | Intravitreal | “Intravitreal (IVT) injection” NCT06506305 ↗ |